-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed Presents 24-Week Biomarker Data From Participants Enrolled In US Cohort Of Phase 2a Clinical Trial Of Neflamapimod, Oral P38α Inhibitor, In Nonfluent Variant Primary Progressive Aphasia, At CTAD Conference

Benzinga·11/16/2026 21:04:59
Listen to the news

24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage 

Full 24-week biomarker and clinical data expected in the first quarter of 2027

Nonfluent variant primary progressive aphasia is a rare progressive neurodegenerative brain condition with no approved disease modifying treatments

BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company) today presented 24-week biomarker data from participants enrolled in the United States (U.S.) cohort of its Phase 2a clinical trial of neflamapimod, an oral p38α inhibitor, in nonfluent variant primary progressive aphasia (nfvPPA), a major subtype of frontotemporal dementia (FTD). Study participants who were in the upper third of plasma drug levels of neflamapimod showed a reduction in plasma neurofilament light chain (NfL), a key biomarker of neuronal damage that increases over time in patients with nfvPPA. The findings were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston.